These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
354 related articles for article (PubMed ID: 26133566)
1. Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. Nicolau DP; Siew L; Armstrong J; Li J; Edeki T; Learoyd M; Das S J Antimicrob Chemother; 2015 Oct; 70(10):2862-9. PubMed ID: 26133566 [TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy Volunteers. Dimelow R; Wright JG; MacPherson M; Newell P; Das S Drugs R D; 2018 Sep; 18(3):221-230. PubMed ID: 30054895 [TBL] [Abstract][Full Text] [Related]
3. Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies. Merdjan H; Rangaraju M; Tarral A Clin Drug Investig; 2015 May; 35(5):307-17. PubMed ID: 25813217 [TBL] [Abstract][Full Text] [Related]
4. Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam. Das S; Armstrong J; Mathews D; Li J; Edeki T J Clin Pharmacol; 2014 Mar; 54(3):331-40. PubMed ID: 24150927 [TBL] [Abstract][Full Text] [Related]
5. Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers. Tominaga N; Edeki T; Li J; Learoyd M; Bouw MR; Das S J Infect Chemother; 2015 Aug; 21(8):551-8. PubMed ID: 26076867 [TBL] [Abstract][Full Text] [Related]
6. Ecological effect of ceftazidime/avibactam on the normal human intestinal microbiota. Rashid MU; Rosenborg S; Panagiotidis G; Löfdal KS; Weintraub A; Nord CE Int J Antimicrob Agents; 2015 Jul; 46(1):60-5. PubMed ID: 25979639 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice. Berkhout J; Melchers MJ; van Mil AC; Seyedmousavi S; Lagarde CM; Nichols WW; Mouton JW Antimicrob Agents Chemother; 2015 Apr; 59(4):2299-304. PubMed ID: 25645843 [TBL] [Abstract][Full Text] [Related]
8. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. Lucasti C; Popescu I; Ramesh MK; Lipka J; Sable C J Antimicrob Chemother; 2013 May; 68(5):1183-92. PubMed ID: 23391714 [TBL] [Abstract][Full Text] [Related]
9. Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients. Bradley JS; Armstrong J; Arrieta A; Bishai R; Das S; Delair S; Edeki T; Holmes WC; Li J; Moffett KS; Mukundan D; Perez N; Romero JR; Speicher D; Sullivan JE; Zhou D Antimicrob Agents Chemother; 2016 Oct; 60(10):6252-9. PubMed ID: 27503642 [TBL] [Abstract][Full Text] [Related]
10. Steady-State Ceftazidime-Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration. Soukup P; Faust AC; Edpuganti V; Putnam WC; McKinnell JA Pharmacotherapy; 2019 Dec; 39(12):1216-1222. PubMed ID: 31596506 [TBL] [Abstract][Full Text] [Related]
11. Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment. Merdjan H; Tarral A; Das S; Li J J Clin Pharmacol; 2017 Feb; 57(2):211-218. PubMed ID: 27402250 [TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Ceftazidime-Avibactam in the Treatment of Children ≥3 Months to <18 Years With Complicated Urinary Tract Infection: Results from a Phase 2 Randomized, Controlled Trial. Bradley JS; Roilides E; Broadhurst H; Cheng K; Huang LM; MasCasullo V; Newell P; Stone GG; Tawadrous M; Wajsbrot D; Yates K; Gardner A Pediatr Infect Dis J; 2019 Sep; 38(9):920-928. PubMed ID: 31335570 [TBL] [Abstract][Full Text] [Related]
13. A Randomized, Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Ceftazidime-Avibactam in Healthy Chinese Subjects. Li J; Learoyd M; Qiu F; Zhu L; Edeki T Clin Drug Investig; 2016 Feb; 36(2):119-26. PubMed ID: 26649741 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Vazquez JA; González Patzán LD; Stricklin D; Duttaroy DD; Kreidly Z; Lipka J; Sable C Curr Med Res Opin; 2012 Dec; 28(12):1921-31. PubMed ID: 23145859 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients. Stein GE; Smith CL; Scharmen A; Kidd JM; Cooper C; Kuti J; Mitra S; Nicolau DP; Havlichek DH Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195 [TBL] [Abstract][Full Text] [Related]
16. Efficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model. Housman ST; Crandon JL; Nichols WW; Nicolau DP Antimicrob Agents Chemother; 2014; 58(3):1365-71. PubMed ID: 24342641 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration. Wenzler E; Bunnell KL; Bleasdale SC; Benken S; Danziger LH; Rodvold KA Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416553 [TBL] [Abstract][Full Text] [Related]
18. Safety Profile of Ceftazidime-Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme. Cheng K; Newell P; Chow JW; Broadhurst H; Wilson D; Yates K; Wardman A Drug Saf; 2020 Aug; 43(8):751-766. PubMed ID: 32602065 [TBL] [Abstract][Full Text] [Related]
19. Review of Clinical Pharmacokinetics of Avibactam, A Newly Approved non-β lactam β-lactamase Inhibitor Drug, In Combination Use With Ceftazidime. Giri P; Patel H; Srinivas NR Drug Res (Stuttg); 2019 May; 69(5):245-255. PubMed ID: 30296806 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia. Falcone M; Viale P; Tiseo G; Pai M Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):331-340. PubMed ID: 29373935 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]